Regression of non-alcoholic fatty liver by vitamin D supplement: A double-blind randomized controlled clinical trial

Archives of Iranian Medicine

Volumn 19, Issue 9, 2016, Pages 631-638

  Lorvand Amiri, Hamid ^a   Agah, Shahram ^b   Mousavi, Seyedeh Neda ^c   Hosseini, Agha Fatemeh ^a   Shidfar, Farzad ^a,b  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anthropometry; Calcitriol; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCITRIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN D;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID STORAGE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; VITAMIN SUPPLEMENTATION; BLOOD; DIAGNOSTIC IMAGING; DIETARY SUPPLEMENT; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; IRAN; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADULT; BLOOD GLUCOSE; CALCITRIOL; CHOLESTEROL, HDL; DIET, REDUCING; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; IRAN; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; TRIGLYCERIDES; ULTRASONOGRAPHY; VITAMIN D;

EID: 84987606110     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Choi HS, Kim KA, Lim CY, Rhee SY, Hwang YC, Kim KM, et al. Low serum vitamin D is associated with high risk of diabetes in Korean adults. The Journal of Nutrition. 2011; 141(8): 1524-1528.
2. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology. 2010; 51(6): 1979-1987.
3. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Advances in Anatomic Pathology. 2002; 9(1): 37-51.
4. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. Journal of Hepatology. 2008; 48: S104-S112.
5. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. International Journal of Obesity. 1998; 22(3): 222-226.
6. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. The Journal of Clinical Endocrinology & Metabolism. 1999; 84(5): 1513-1517.
7. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005; 42(1): 44-52.
8. Browning JD, Szczepaniak LS, Dobbins R, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6): 1387-1395.
9. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Japanese Journal of Medicine. 1988; 27(2): 142-149.
10. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. The American Journal of Gastroenterology. 2004; 99(12): 2365-2368.
11. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Alimentary Pharmacology & Therapeutics. 2004; 20(6): 623-628.
12. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. The American Journal of Gastroenterology. 2005; 100(5): 1082-1090.
13. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine. 2010; 362(18): 1675-1685.
14. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004; 39(3): 770-778.
15. Merat S, Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, et al. Probucol in the treatment of nonalcoholic steatohepatitis: An open-labeled study. Journal of Clinical Gastroenterology. 2003; 36(3): 266-268.
16. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004; 53(8): 2169-2216.
17. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology. 2003; 38(4): 1008-1017.
18. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004; 39(1): 188-196.
19. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New England Journal of Medicine. 2006; 355(22): 2297-2307.
20. Yetley EA. Assessing the vitamin D status of the US population. The American Journal of Clinical Nutrition. 2008; 88(2): 558S-564S.
21. Holick MF. Vitamin D deficiency. New England Journal of Medicine. 2007; 357(3): 266-281.
22. Flores M. A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus? Nutrition Research Reviews. 2005; 18(2): 175-182.
23. James WP. 22nd Marabou Symposium: the changing faces of vitamin D. Nutrition Reviews. 2008; 66(Suppl 2): S213-S217.
24. Barchetta I, Angelico F, Ben MD, Baroni MG, Pozzilli P, Morini S, et al. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25 (OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Medicine. 2011; 9(1): 85.
25. Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. Journal of Hepatology. 2011; 55(2): 415-425.
26. Rhee EJ, Kim MK, Park SE, Park CY, Baek KH, Lee WY, et al. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocrine Journal. 2013; 60(6): 743-752.
27. Jacqmain M, Doucet E, Després JP, Bouchard C, Tremblay A. Calcium intake, body composition, and lipoprotein-lipid concentrations in adults. The American Journal of Clinical Nutrition. 2003; 77(6): 1448-1452.
28. Major GC, Alarie F, Doré J, Phouttama S, Tremblay A. Supplementation with calcium+ vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. The American Journal of Clinical Nutrition. 2007 Jan 1; 85(1): 54-59.
29. Li L, Zhang L, Pan S, Wu X, Yin X. No significant association between vitamin D and nonalcoholic fatty liver disease in a Chinese population. Digestive Diseases and Sciences. 2013; 58(8): 2376-2382.
30. Katz K, Brar PC, Parekh N, Liu YH, Weitzman M. Suspected nonalcoholic fatty liver disease is not associated with vitamin D status in adolescents after adjustment for obesity. Journal of Obesity. 2011; 2010: 496829.
31. Forouhi NG, Luan JA, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance the medical research council ely prospective study 1990-2000. Diabetes. 2008; 57(10): 2619-2625.
32. Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, et al. The relationship between obesity and serum 1, 25-dihydroxy vitamin D concentrations in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2004; 89(3): 1196-1199.
33. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Annals of Internal Medicine. 2010; 152(5): 307-314.
34. Geier A. Shedding new light on vitamin D and fatty liver disease. Journal of Hepatology. 2011; 55(2): 273-275.
35. Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. Journal of Hepatology. 2011; 55(2): 415-425.
36. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology. 2012; 55(4): 1103-1111.
37. Piccoli A, Rossi B, Pillon L, Bucciante G. A new method for monitoring body fluid variation by bioimpedance analysis: The RXc graph. Kidney International. 1994; 46: 534-539.
38. Hosseini Esfahani F, Asghari G, Mirmiran P, Azizi F. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the Tehran Lipid and Glucose Study. Journal of Epidemiology. 2010; 20(2): 150-158.
39. Booth ML, Ainsworth BE, Pratt MI, Ekelund U, Yngve AG, Sallis JF, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003; 195(9131/03): 1381-1395
40. Wilson SR, Withers CE. The Liver. In: Rumack CM, Wilson SR, Charboneau JW, editors. Diagnostic Ultrasound. 3rd ed. St. Louis: Elsevier Mosby; 2005. 95-96.
41. Rajpathak SN, Xue X, Wassertheil-Smoller S, Van Horn L, Robinson JG, Liu S, et al. Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: Results from the Women’s Health Initiative. The American Journal of Clinical Nutrition. 2010; 91(4): 894-899.
42. Salehpour A, Hosseinpanah F, Shidfar F, Vafa M, Razaghi M, Dehghani S, et al. A 12-week double-blind randomized clinical trial of vitamin D3 supplementation on body fat mass in healthy overweight and obese women. Nutr J. 2012; 11(1): 78.
43. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. Associations between serum 25-hydroxyvitamin D 3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases. 2007; 17(7): 517-524.
44. Barchetta I, Angelico F, Ben MD, Baroni MG, Pozzilli P, Morini S, et al. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25 (OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Medicine. 2011; 9(1): 85.
45. Mian Li, Yu Xu, Min Xu, Lingying Ma, Tiange Wang, Yu Liu, et al. Association between non-alcoholic fatty liver disease (NAFLD) and osteoprotic fracture in middle-aged and elderly chinese men. J Clin Endocrinol Metab. 2012; 97(6): 2033-2038.
46. Yilmaz Y. Non-alcoholic fatty liver disease and osteoporosis-clinical and molecular crosstalk. Aliment Pharmacol Ther. 2012; 36: 345-352.
47. Siddiqui SM, Chang E, Li J, Burlage C, Zou M, Buhman KK, et al. Dietary intervention with vitamin D, calcium, and whey protein reduced fat mass and increased lean mass in rats. Nutrition Research. 2008; 28(11): 783-790.
48. Rosenblum JL, Castro VM, Moore CE, Kaplan LM. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. The American Journal of Clinical Nutrition. 2012; 95(1): 101-108.
49. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010, 95: 471-478.
50. Reid IR. Relationships between fat and bone. Osteoporos Int. 2008, 19: 595-606.
51. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta- analysis. The Journal of Clinical Endocrinology & Metabolism. 2007; 92(6): 2017-2029.
52. Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: A systematic review. European Journal of Clinical Nutrition. 2011; 65(9): 1005-15.
53. George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabetic Medicine. 2012; 29(8): e142-e150.
54. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. The FASEB Journal. 2003; 17(3): 509-511.
55. Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 2013; 38(3): 246-254.
56. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. Associations between serum 25-hydroxyvitamin D 3 concentrations and liver histology in patients with non- alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases. 2007; 17(7): 517-524.
57. Abawi MBA, Baranova A, Afendy A, Page S, Stepanova M. Vitamin D levels in non-alcoholic fatty liver disease (NAFLD) patients correlate with apoptosis and serum levels of M30. Am J Gastroenterol. 2011; 106: S121.
58. Dasarathy JPP, Allampati S, Hawkins CA, Brandt PT, Khiyami A, McCullough AJ, et al. Hypovitaminosis D associated with more advanced non-alcoholic fatty liver disease. Hepatology. 2012; 56(S1): 889A-890A.
59. M Manco M, Ciampalini P, Nobili V. Low levels of 25-hydroxyvitamin D3 in children with biopsy-proven nonalcoholic fatty liver disease. Hepatology. 2010; 51(6): 2229-2230.
60. Nobili V, Giorgio V, Liccardo D, Bedogni G, Morino G, Alisi A, et al. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. European Journal of Endocrinology. 2014; 170(4): 547-553.
61. Ju SY, Jeong HS, Kim DH. Blood vitamin D status and metabolic syndrome in the general adult population: A dose-response meta- analysis. The Journal of Clinical Endocrinology & Metabolism. 2013; 99(3): 1053-1063.
62. Myrto Eliades, Elias Spyrou. Vitamin D: A new player in non-alcoholic fatty liver disease? World J Gastroenterol. 2015; 21(6): 1718-1727.
63. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia. 1995; 38(10): 1239-1245.
64. Nagpal J, Pande JN, Bhartia A. A double-blind randomized placebo- controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabetic Medicine. 2009; 26(1): 19-27.
65. Pinelli NR, Jaber LA, Brown MB, Herman WH. Serum 25-hydroxy vitamin D and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care. 2010; 33(6): 1373-1375.
66. Hoseini SA, Aminorroaya A, Iraj B, Amini M. The effects of oral vitamin D on insulin resistance in pre-diabetic patients. Journal of research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2013; 18(1): 47.